Home › BPCIA: Amgen Begins the Patent Dance With AbbVie
 

Keywords :   


BPCIA: Amgen Begins the Patent Dance With AbbVie

2015-12-08 00:56:18| Biotech - Topix.net

On November 25, 2015, Amgen Inc. announced it submitted its first biologics license application to the FDA under the Section 351 biosimilar approval pathway provided in the Biologics Price Competition and Innovation Act . Amgen's BLA seeks approval for its biosimilar of AbbVie's top-selling arthritis drug Humira .

Tags: dance begins patent amgen

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »